CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Revenue by Segment

Period Ending	Dec 31, 2024	Dec 31, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017
Collaboration	405.00M	370.01M	170.10M	100.26M	436.00K	12.78M	13.01M	913.06M
Collaboration Growth	92,789.91%	2,795.65%	1,207.15%	-89.02%	-99.95%	-98.58%	-98.56%	155,181.80%
Grant	2.31M	3.01M	-	-	-	-	-	2.31M			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant Growth	-23.22%	-	-	-	-	-	-	-			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Operating Expense Breakdown

Period Ending	Dec 31, 2024	Dec 31, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Research and Development	320.65M	387.33M
Research and Development Growth	-17.22%	-16.10%
Collaboration	-	130.25M	132.51M							-	-	-	-	-	-	-	-	-	-
Collaboration Growth	-	18.14%	11.49%							-	-	-	-	-	-	-	-	-	-
General and Administrative	72.98M	76.16M
General and Administrative Growth	-4.18%	-25.67%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.